We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mutated Gene Biomarker Identified for Rare Adrenal Tumors

By LabMedica International staff writers
Posted on 04 Feb 2015
A mutation in a gene has been found that may serve as a biomarker for the rare adrenal tumors pheochromocytomas and paragangliomas that become malignant.

Pheochromocytomas and paragangliomas (PCC/PGL) are tumors of the autonomic nervous system arising from the adrenal medulla and extra-adrenal ganglia, respectively. PCC/PGL are more commonly associated with inherited susceptibility gene mutations than any other solid tumor.

Image: The Qubit 3.0 Fluorometer (Photo courtesy of Life Technologies).
Image: The Qubit 3.0 Fluorometer (Photo courtesy of Life Technologies).

Scientists at the Perelman School of Medicine (Philadelphia, PA, USA) used a set of 21 PCC/PGL that were selected to represent clinically benign and clinically aggressive tumors. Fresh-frozen PCC/PGL were sectioned and stained with hematoxylin and eosin to ensure sections of over 70% tumors are used for DNA extraction. Germline DNA from blood or saliva was extracted using standard protocols in the laboratory.

All DNA was quantitated with a Qubit fluorometer (Life Technologies; Carlsbad, CA, USA). To ensure high-quality genomic DNA, the A260/280 ratio was measured on a Nanodrop (Wilmington, DE, USA) and DNA was run on a 1% agarose gel. Whole-exome sequencing was performed on fresh-frozen tumor and matched germline DNA and DNA quality and fragment size were measured with an Agilent 2100 Bioanalyzer (Santa Clara, CA, USA) and concentration measured with a Qubit fluorometer.

The team reported that somatic alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutations were identified in two of seven succinate dehydrogenase complex, subunit B, iron sulfur (SDHB)-associated tumors. To determine the frequency of somatic ATRX mutations in PCC/PGL, the team sequenced the ATRX coding region in a separate set of 103 tumors samples. They found that 13% of tumors had ATRX mutations.

The authors concluded that although the sample set of PCC/PGL with ATRX variants is too small to identify statistically significant associations, many had clinically aggressive features, inherited succinate dehydrogenase (SDHx) mutations and alternative lengthening of telomeres (ALT), suggesting an interaction between the somatic and inherited genomes in solid cancers, which needs to be investigated further. The study was published on January 21, 2015, in the journal Nature Communications.

Related Links:

Perelman School of Medicine
Life Technologies
Nanodrop 



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Thyroxine ELISA
T4 ELISA
New
Newborn Screening Test
NeoMass AAAC 3.0

Latest Pathology News

New Microscopy Method Enables Detailed Whole Brain 3D RNA Analysis

AI Model Identifies Signs of Disease Faster and More Accurately Than Humans

New Barcode Technology to Help Diagnose Cancer More Precisely